Seattle, WA -- (SBWIRE) -- 10/02/2019 -- Diabetes is a medical condition where the level of sugar in the blood is too high and is one of the most prevalent chronic diseases around the globe. According to WHO (World Health Organization), diabetes was one of the top three leading causes of mortality in 2012. Currently, the diabetes vaccine is under development process which has great potential in younger age population (Below 20 years age), who have a strong autoimmune response to fight against infection from specific viruses. Diabetes vaccine is developed to strengthen the body's response to enterovirus which is called as coxsackievirus B1, it senses enterovirus and secretes immune response to kill it. Therefore, it kills the insulin produced by the beta cell in the pancreas, which is associated with type 1 diabetes disease. Although, there is no approved diabetes vaccine available in the market, however major players are focusing on increasing more research to produce such vaccines by targeting different process that stimulates the autoimmune response.
Rising prevalence of type 1 diabetes is projected to support the market growth of diabetes vaccine over the forecast timeline
Increasing global prevalence and incidence of type 1 diabetes is, predominantly expected to create a lucrative growth opportunity for market growth of the diabetes vaccine According to the International Diabetes Federation's (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide by the end of 2017. Of this, one million people (children and adolescents below 20 years of age) are suffering from type 1 diabetes, with around 150,000 new cases reported each year.
Moreover, patients with type 1 diabetes require regular monitoring and also require insulin externally, which is administered intramuscularly every day this can be scary for children. Also, the cost associated with insulin therapy is much high, which is further projected to encourage market growth.
Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/1367
Market Segmentation
By age group
- Up to 20 years of age
- Above 20 years of age
By End-user
- Hospitals
- Clinics
- Others
North America market is presumed to gain high growth, followed by Europe and Asia Pacific markets over the forecast timeline
North America is projected to experience high growth in the global diabetes vaccine market over the forecast timeline and this can be attributed to rising incidence of diabetes and high investment in healthcare infrastructure in the U.S. For instance, according to IDF, 17,100 new cases were detected in 2017 in the U.S. Around US$ 377 billion was spent over entire diabetes disease range, which accounts for about 52% of the total healthcare expenditure on diabetes worldwide. A significant part of which goes into maintaining constant blood sugar in type 1 by the use of insulin. According to statistics released by the American Diabetes Association, in 2017, around 193,000 people under 20 years of age in the U.S. were estimated to be diagnosed with diabetes, which accounts for 0.24% of this population. This inadvertently is projected to offer room for a growth opportunity to the market. U.S. has the maximum number of children and adolescent (under age 20) with Type 1 diabetes at a range of 1,69,600 in 2017, this is followed by India with the highest cases type 1 diabetes after the U.S at a range of 1,28,500 as reported by IDF.
In-Depth Study of TOC & Direct Purchase Report @https://www.coherentmarketinsights.com/insight/buy-now/1367
Developments in the diabetes vaccine market
Imcys— a Belgium-based biotech company— announced plans to commence its clinical trial in 2018 for new diabetes vaccine to treat type 1 diabetes. It uses modified peptides called imotopes, which spurs specific type of immune cell to kill immune cells that work on the insulin producing beta cells.
Moreover, in 2017, Massachusetts General Hospital Immunobiology Laboratory presented findings of clinical trial at 75th Scientific Sessions of the American Diabetes Association, related to use of BCG vaccine to treat autoimmune response in type 1 diabetes. BCG vaccine could induce a permanent gene expression that restores regulatory T cells, thereby preventing the immune system attack, which is observed in type 1 diabetes. It is currently under phase two clinical trial.
Browse For More Information: https://www.coherentmarketinsights.com/ongoing-insight/diabetes-vaccine-market-1367
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.